Citations (152)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Laurent Simon. (2023) Estimation of Volatile Organic Compound Exposure Concentrations and Time to Reach a Specific Dermal Absorption Using Physiologically Based Pharmacokinetic Modeling. Journal of Occupational and Environmental Hygiene 0:0, pages 1-34.
Read now
Read now
Xue-Feng Lu, Jian Zhan, Yang Zhou, Kai-Shun Bi & Xiao-Hui Chen. (2017) Use of a semi-physiological pharmacokinetic model to investigate the influence of itraconazole on tacrolimus absorption, distribution and metabolism in mice. Xenobiotica 47:9, pages 752-762.
Read now
Read now
Sihem Ait-Oudhia, Meric Ayse Ovacik & Donald E. Mager. (2017) Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity. mAbs 9:1, pages 15-28.
Read now
Read now
Xue-Feng Lu, Kaishun Bi & Xiaohui Chen. (2016) Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes. Xenobiotica 46:12, pages 1093-1104.
Read now
Read now
Mirjam Luijten, Evelyn D. Olthof, Betty C. Hakkert, Emiel Rorije, Jan-Willem van der Laan, Ruud A. Woutersen & Jan van Benthem. (2016) An integrative test strategy for cancer hazard identification. Critical Reviews in Toxicology 46:7, pages 615-639.
Read now
Read now
Sumon Chakraborty, Lokesh Yadav & Deepika Aggarwal. (2015) Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products. Drug Development and Industrial Pharmacy 41:10, pages 1667-1673.
Read now
Read now
Lei Diao & Bernd Meibohm. (2015) Tools for predicting the PK/PD of therapeutic proteins. Expert Opinion on Drug Metabolism & Toxicology 11:7, pages 1115-1125.
Read now
Read now
Gerald Bachler, Natalie von Goetz & Konrad Hungerbuhler. (2015) Using physiologically based pharmacokinetic (PBPK) modeling for dietary risk assessment of titanium dioxide (TiO2) nanoparticles. Nanotoxicology 9:3, pages 373-380.
Read now
Read now
Christian Höcht, Facundo Martín Bertera, Julieta Sofía Del Mauro & Carlos Alberto Taira. (2014) Models for evaluating the pharmacokinetics and pharmacodynamics for β-blockers. Expert Opinion on Drug Metabolism & Toxicology 10:4, pages 525-541.
Read now
Read now
Karen Rowland Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2013) Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Review of Clinical Pharmacology 6:2, pages 143-157.
Read now
Read now
Jennifer B Dressman, Kirstin Thelen & Stefan Willmann. (2011) An update on computational oral absorption simulation. Expert Opinion on Drug Metabolism & Toxicology 7:11, pages 1345-1364.
Read now
Read now
Andrea N Edginton & Ghanashyam Joshi. (2011) Have physiologically-based pharmacokinetic models delivered?. Expert Opinion on Drug Metabolism & Toxicology 7:8, pages 929-934.
Read now
Read now
Charlotte Kloft & Italo Poggesi. (2010) Current and future directions of pharmacokinetic and pharmacokinetic–pharmacodynamic modelling and simulation: Population Approach Group in Europe 19th annual meeting. Expert Opinion on Drug Metabolism & Toxicology 6:12, pages 1599-1604.
Read now
Read now
Elaine
A. Cohen Hubal, Ann Richard, Lesa Aylward, Steve Edwards, Jane Gallagher, Michael-Rock Goldsmith, Sastry Isukapalli, Rogelio Tornero-Velez, Eric Weber & Robert Kavlock. (2010) Advancing Exposure Characterization for Chemical Evaluation and Risk Assessment. Journal of Toxicology and Environmental Health, Part B 13:2-4, pages 299-313.
Read now
Read now
Kaizhen Chen, Shiyi Teo & Kok-Yong Seng. (2009) Sensitivity analysis on a physiologically-based pharmacokinetic and pharmacodynamic model for diisopropylfluorophosphate-induced toxicity in mice and rats. Toxicology Mechanisms and Methods 19:8, pages 486-497.
Read now
Read now
Nikoletta Fotaki. (2009) Pros and cons of methods used for the prediction of oral drug absorption. Expert Review of Clinical Pharmacology 2:2, pages 195-208.
Read now
Read now
Andrea N Edginton, Frank-Peter Theil, Walter Schmitt & Stefan Willmann. (2008) Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opinion on Drug Metabolism & Toxicology 4:9, pages 1143-1152.
Read now
Read now
Stefan S De Buck & Claire E Mackie. (2007) Physiologically based approaches towards the prediction of pharmacokinetics: in vitro–in vivo extrapolation. Expert Opinion on Drug Metabolism & Toxicology 3:6, pages 865-878.
Read now
Read now
T. Lavé, N. Parrott, H. P. Grimm, A. Fleury & M. Reddy. (2007) Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 37:10-11, pages 1295-1310.
Read now
Read now
Articles from other publishers (133)
Mo’tasem M. Alsmadi. (2023) Evaluating the Pharmacokinetics of Fentanyl in the Brain Extracellular Fluid, Saliva, Urine, and Plasma of Newborns from Transplacental Exposure from Parturient Mothers Dosed with Epidural Fentanyl Utilizing PBPK Modeling. European Journal of Drug Metabolism and Pharmacokinetics.
Crossref
Crossref
Mo’tasem M. Alsmadi & Nasir Idkaidek. (2023) The Analysis of Pethidine Pharmacokinetics in Newborn Saliva, Plasma, and Brain Extracellular Fluid After Prenatal Intrauterine Exposure from Pregnant Mothers Receiving Intramuscular Dose Using PBPK Modeling. European Journal of Drug Metabolism and Pharmacokinetics 48:3, pages 281-300.
Crossref
Crossref
Mo'tasem M. Alsmadi, Laith N. AL Eitan, Nasir M. Idkaidek & Karem H. Alzoubi. (2022) The Development of a PBPK Model for Atomoxetine Using Levels in Plasma,
Saliva and Brain Extracellular Fluid in Patients with Normal and Deteriorated
Kidney Function. CNS & Neurological Disorders - Drug Targets 21:8, pages 704-716.
Crossref
Crossref
Mo’tasem M. Alsmadi, Nour M. AL-Daoud, Rana M. Obaidat & Niazy A. Abu-Farsakh. (2022) Enhancing Atorvastatin In Vivo Oral Bioavailability in the Presence of Inflammatory Bowel Disease and Irritable Bowel Syndrome Using Supercritical Fluid Technology Guided by wbPBPK Modeling in Rat and Human. AAPS PharmSciTech 23:5.
Crossref
Crossref
Lujing Wang, Yang Chen, Wangda Zhou, Xin Miao & Honghui Zhou. (2021) Utilization of physiologically‐based pharmacokinetic model to assess disease‐mediated therapeutic protein‐disease‐drug interaction in immune‐mediated inflammatory diseases. Clinical and Translational Science 15:2, pages 464-476.
Crossref
Crossref
Largee Biswas, Asiya Mahtab & Anita K. Verma. 2022. Nanoparticle Therapeutics. Nanoparticle Therapeutics
265
289
.
Ankit Balhara, Sumeet Kale & Saranjit Singh. 2022. Computer Aided Pharmaceutics and Drug Delivery. Computer Aided Pharmaceutics and Drug Delivery
255
284
.
Manuel Ibarra, Alejandra Schiavo & Lawrence J. Lesko. 2022. The ADME Encyclopedia. The ADME Encyclopedia
987
995
.
Manreet KaurVanessa YardleyKe WangJinit MasaniaRandolph R. J. Arroo, David B. TurnerMingzhong Li. (2021)
Artemisinin Cocrystals for Bioavailability Enhancement. Part 2:
In Vivo
Bioavailability and Physiologically Based Pharmacokinetic Modeling
. Molecular Pharmaceutics 18:12, pages 4272-4289.
Crossref
Crossref
Michael Monine, Daniel Norris, Yanfeng Wang & Ivan Nestorov. (2021) A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration. Journal of Pharmacokinetics and Pharmacodynamics 48:5, pages 639-654.
Crossref
Crossref
Georgi I. Kapitanov, Jeffrey R. Chabot, Jatin Narula, Mahua Roy, Hendrik Neubert, Joe Palandra, Vahid Farrokhi, Jay S. Johnson, Robert Webster & Hannah M. Jones. (2021) A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs. Frontiers in Bioinformatics 1.
Crossref
Crossref
Mo'tasem M. Alsmadi, Nour M AL‐Daoud, Mays M. Jaradat, Saja B. Alzughoul, Amani D. Abu Kwiak, Salam S. Abu Laila, Ayat J. Abu Shameh, Mohammad K. Alhazabreh, Sana'a A. Jaber & Hala T. Abu Kassab. (2021) Physiologically‐based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment. Biopharmaceutics & Drug Disposition 42:6, pages 263-284.
Crossref
Crossref
Takafumi Kato, Tsuyoshi Mikkaichi, Yasushi Yoshigae, Noriko Okudaira, Takako Shimizu, Takashi Izumi, Shuichi Ando & Yoshiaki Matsumoto. (2021) Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model. International Journal of Pharmaceutics 597, pages 120349.
Crossref
Crossref
Eric Salgado & Yanguang Cao. (2021) Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes. Mathematical Biosciences and Engineering 18:1, pages 112-131.
Crossref
Crossref
Manuel Ibarra, Alejandra Schiavo & Lawrence J. Lesko. 2021. The ADME Encyclopedia. The ADME Encyclopedia
1
9
.
V. Kumar, Deepika Deepika & R. P. Sharma. 2020. Challenges in Endocrine Disruptor Toxicology and Risk Assessment. Challenges in Endocrine Disruptor Toxicology and Risk Assessment
80
120
.
Nasir Idkaidek, Salim Hamadi, Rabab Bani-Domi, Ibrahim Al-Adham, Motasem Alsmadi, Faten Awaysheh, Hisham Aqrabawi, Ahmad Al-Ghazawi & Ayman Rabayah. (2020) Saliva versus Plasma Therapeutic Drug Monitoring of Gentamicin in
Jordanian Preterm Infants. Development of a Physiologically-Based
Pharmacokinetic (PBPK) Model and Validation of Class II Drugs of Salivary
Excretion Classification System. Drug Research 70:10, pages 455-462.
Crossref
Crossref
Mariam A. Ahmed, Chirag PatelNicole Drezner, Whitney Helms, Weiwei Tan & Daria Stypinski. (2019) Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development. Clinical and Translational Science 13:1, pages 31-40.
Crossref
Crossref
Jong Hyuk Byun, Dong-Gyun Han, Hyun-Jong Cho, In-Soo Yoon & Il Hyo Jung. (2020) Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines. Archives of Pharmacal Research 43:1, pages 80-99.
Crossref
Crossref
Sebastiaan D.T. Sassen, C. Michel Zwaan, Inge M. der Sluis & Ron A.A. Mathôt. (2019) Pharmacokinetics and population pharmacokinetics in pediatric oncology. Pediatric Blood & Cancer.
Crossref
Crossref
Mo'tasem M. Alsmadi, Mahdi Qasem Alfarah, Jawaher Albderat, Ghazi Alsalaita, Reham AlMardini, Salim Hamadi, Ahmad Al‐Ghazawi, Omar Abu‐Duhair & Nasir Idkaidek. (2019) The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue. Biopharmaceutics & Drug Disposition 40:9, pages 325-340.
Crossref
Crossref
Shan Pan & Stephen B. Duffull. (2019) Automated proper lumping for simplification of linear physiologically based pharmacokinetic systems. Journal of Pharmacokinetics and Pharmacodynamics 46:4, pages 361-370.
Crossref
Crossref
Guthrie Miller, John A. Klumpp, Deepesh Poudel, Waylon Weber, Raymond A. Guilmette, Jasen Swanson & Dunstanta R. Melo. (2019) Americium Systemic Biokinetic Model for Rats. Radiation Research 192:1, pages 75.
Crossref
Crossref
María Elena Bravo-Gómez, Laura Nayeli Camacho-García, Luz Alejandra Castillo-Alanís, Miguel Ángel Mendoza-Meléndez & Alejandra Quijano-Mateos. (2019) Revisiting a physiologically based pharmacokinetic model for cocaine with a forensic scope. Toxicology Research 8:3, pages 432-446.
Crossref
Crossref
Joshua C. Euteneuer, Suyog Kamatkar, Tsuyoshi Fukuda, Alexander A. Vinks & Henry T. Akinbi. (2019) Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy. The Journal of Clinical Pharmacology 59:2, pages 168-176.
Crossref
Crossref
Najia Mansoor, Tasneem Ahmad, Rafeeq Alam Khan, Syed Mohammad Sharib & Iftekhar Mahmood. (2019) Prediction of Clearance and Dose of Midazolam in Preterm and Term Neonates: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling. American Journal of Therapeutics 26:1, pages e32-e37.
Crossref
Crossref
Shinji Yamazaki, Cho-Ming Loi, Emi Kimoto, Chester Costales & Manthena V. Varma. (2018) Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein. Drug Metabolism and Disposition 46:8, pages 1200-1211.
Crossref
Crossref
Iftekhar Mahmood & Million A. Tegenge. (2018) Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations. Regulatory Toxicology and Pharmacology 97, pages 57-62.
Crossref
Crossref
Anum Munir, Shumaila Azam, Sahar Fazal & A.I. Bhatti. (2018) Evaluation of the whole body physiologically based pharmacokinetic (WB-PBPK) modeling of drugs. Journal of Theoretical Biology 451, pages 1-9.
Crossref
Crossref
Navpreet Kaur, Ajit Narang & Arvind Kumar Bansal. (2018) Use of biorelevant dissolution and PBPK modeling to predict oral drug absorption. European Journal of Pharmaceutics and Biopharmaceutics 129, pages 222-246.
Crossref
Crossref
Nusrat J. Begum, Anne Thieme, Nina Eberhardt, Robert Tauber, Calogero D’Alessandria, Ambros J. Beer, Gerhard Glatting, Matthias Eiber & Peter Kletting. (2018)
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for
177
Lu-Labeled PSMA Peptides
. Journal of Nuclear Medicine 59:6, pages 929-933.
Crossref
Crossref
Alexis Viel, Jérôme Henri, Salim Bouchène, Julian Laroche, Jean-Guy Rolland, Jacqueline Manceau, Michel Laurentie, William Couet & Nicolas Grégoire. (2018) A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion. Pharmaceutical Research 35:5.
Crossref
Crossref
Christoph Niederalt, Lars Kuepfer, Juri Solodenko, Thomas Eissing, Hans-Ulrich Siegmund, Michael Block, Stefan Willmann & Jörg Lippert. (2017) A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim. Journal of Pharmacokinetics and Pharmacodynamics 45:2, pages 235-257.
Crossref
Crossref
Nadine Schaefer, Daniel Moj, Thorsten Lehr, Peter H. Schmidt & Frank Ramsthaler. (2017) The feasibility of physiologically based pharmacokinetic modeling in forensic medicine illustrated by the example of morphine. International Journal of Legal Medicine 132:2, pages 415-424.
Crossref
Crossref
Stephen D. Stamatis, Linas Mockus, Lee E. Kirsch & Gintaras V. Reklaitis. 2018. Quantitative Systems Pharmacology - Models and Model-Based Systems with Applications. Quantitative Systems Pharmacology - Models and Model-Based Systems with Applications
111
137
.
G. Johanson. 2018. Comprehensive Toxicology. Comprehensive Toxicology
165
187
.
Panos Lehouritis, Glenn Hogan & Mark Tangney. (2017) Designer bacteria as intratumoural enzyme biofactories. Advanced Drug Delivery Reviews 118, pages 8-23.
Crossref
Crossref
Fiona Sewell, Manoj Aggarwal, Gerald Bachler, Alan Broadmeadow, Nichola Gellatly, Emma Moore, Sally Robinson, Martijn Rooseboom, Alexander Stevens, Claire Terry & Natalie Burden. (2017) The current status of exposure-driven approaches for chemical safety assessment: A cross-sector perspective. Toxicology 389, pages 109-117.
Crossref
Crossref
Ines Thiele, Catherine M. Clancy, Almut Heinken & Ronan M.T. Fleming. (2017) Quantitative systems pharmacology and the personalized drug–microbiota–diet axis. Current Opinion in Systems Biology 4, pages 43-52.
Crossref
Crossref
Siamak P. Nejad-Davarani, Hassan Bagher-Ebadian, James R. Ewing, Douglas C. Noll, Tom Mikkelsen, Michael Chopp & Quan Jiang. (2017) An extended vascular model for less biased estimation of permeability parameters in DCE-T1 images. NMR in Biomedicine 30:6, pages e3698.
Crossref
Crossref
Siamak P. Nejad-Davarani, Hassan Bagher-Ebadian, James R. Ewing, Douglas C. Noll, Tom Mikkelsen, Michael Chopp & Quan Jiang. (2017) A parametric model of the brain vascular system for estimation of the arterial input function (AIF) at the tissue level. NMR in Biomedicine 30:5, pages e3695.
Crossref
Crossref
Julio Lahoz-Beneytez, Stephan Schaller, Derek Macallan, Thomas Eissing, Christoph Niederalt & Becca Asquith. (2017) Physiologically Based Simulations of Deuterated Glucose for Quantifying Cell Turnover in Humans. Frontiers in Immunology 8.
Crossref
Crossref
Chiho Ono, Poe-Hirr Hsyu, Richat Abbas, Cho-Ming Loi & Shinji Yamazaki. (2017) Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug–Drug and Drug–Disease Interactions. Drug Metabolism and Disposition 45:4, pages 390-398.
Crossref
Crossref
Muhammad W. Sadiq, Elisabet I. Nielsen, Dalia Khachman, Jean-Marie Conil, Bernard Georges, Georges Houin, Celine M. Laffont, Mats O. Karlsson & Lena E. Friberg. (2016) A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection. Journal of Pharmacokinetics and Pharmacodynamics 44:2, pages 69-79.
Crossref
Crossref
Kristin J. R. Dickschen, Stefan Willmann, Georg Hempel & Michael Block. (2017) Addressing Adherence Using Genotype-Specific PBPK Modeling—Impact of Drug Holidays on Tamoxifen and Endoxifen Plasma Levels. Frontiers in Pharmacology 8.
Crossref
Crossref
Raju Prasad Sharma, Marta Schuhmacher & Vikas Kumar. (2017) Review on crosstalk and common mechanisms of endocrine disruptors: Scaffolding to improve PBPK/PD model of EDC mixture. Environment International 99, pages 1-14.
Crossref
Crossref
Johannes Hans Proost. 2017. Total Intravenous Anesthesia and Target Controlled Infusions. Total Intravenous Anesthesia and Target Controlled Infusions
117
145
.
Ahmad Rezaei Kolahchi, Nima Khadem Mohtaram, Hassan Pezeshgi Modarres, Mohammad Mohammadi, Armin Geraili, Parya Jafari, Mohsen Akbari & Amir Sanati-Nezhad. (2016) Microfluidic-Based Multi-Organ Platforms for Drug Discovery. Micromachines 7:9, pages 162.
Crossref
Crossref
Francesc Fàbrega, Martí Nadal, Marta Schuhmacher, José L. Domingo & Vikas Kumar. (2016) Influence of the uncertainty in the validation of PBPK models: A case-study for PFOS and PFOA. Regulatory Toxicology and Pharmacology 77, pages 230-239.
Crossref
Crossref
Mark H. Weir. 2016. Manual of Environmental Microbiology. Manual of Environmental Microbiology
3.5.3-1
3.5.3-17
.
Gregory Z. Ferl, Frank‐Peter Theil & Harvey Wong. (2016) Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini‐review on fundamental concepts and applications. Biopharmaceutics & Drug Disposition 37:2, pages 75-92.
Crossref
Crossref
Xiaowen Liang, Haolu Wang, Jeffrey E. Grice, Li Li, Xin Liu, Zhi Ping Xu & Michael S. Roberts. (2016) Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles. Nano Letters 16:2, pages 939-945.
Crossref
Crossref
Markus Krauss & Andreas Schuppert. (2016) Assessing interindividual variability by Bayesian-PBPK modeling. Drug Discovery Today: Disease Models 22, pages 15-19.
Crossref
Crossref
Paulo Paixão, Luís Gouveia, José Augusto Guimarães Morais & Nuno Silva. 2016. Concepts and Models for Drug Permeability Studies. Concepts and Models for Drug Permeability Studies
357
371
.
Thierry Wendling, Swati Dumitras, Kayode Ogungbenro & Leon Aarons. (2015) Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics 42:6, pages 639-657.
Crossref
Crossref
Yulan Wang, Jing Xing, Yuan Xu, Nannan Zhou, Jianlong Peng, Zhaoping Xiong, Xian Liu, Xiaomin Luo, Cheng Luo, Kaixian Chen, Mingyue Zheng & Hualiang Jiang. (2015)
In silico
ADME/T modelling for rational drug design
. Quarterly Reviews of Biophysics 48:4, pages 488-515.
Crossref
Crossref
Tanay S. Samant, Naveen Mangal, Viera Lukacova & Stephan Schmidt. (2015) Quantitative clinical pharmacology for size and age scaling in pediatric drug development: A systematic review. The Journal of Clinical Pharmacology 55:11, pages 1207-1217.
Crossref
Crossref
Markus Krauss, Kai Tappe, Andreas Schuppert, Lars Kuepfer & Linus Goerlitz. (2015) Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations. PLOS ONE 10:10, pages e0139423.
Crossref
Crossref
Eirini Christodoulou, Irene-Ariadne Kechagia, Stavros Tzimas, Evangelos Balafas, Nikolaos Kostomitsopoulos, Helen Archontaki, Aristides Dokoumetzidis & Georgia Valsami. (2015) Serum and tissue pharmacokinetics of silibinin after per os and i.v. administration to mice as a HP-β-CD lyophilized product. International Journal of Pharmaceutics 493:1-2, pages 366-373.
Crossref
Crossref
Armin Sepp, Alienor Berges, Andrew Sanderson & Guy Meno-Tetang. (2015) Development of a physiologically based pharmacokinetic model for a domain antibody in mice using the two-pore theory. Journal of Pharmacokinetics and Pharmacodynamics 42:2, pages 97-109.
Crossref
Crossref
Nikolaos Tsamandouras, Amin Rostami‐Hodjegan & Leon Aarons. (2014)
Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting
PBPK
models to observed clinical data
. British Journal of Clinical Pharmacology 79:1, pages 48-55.
Crossref
Crossref
Marta Schuhmacher, Francesc Fàbrega, Vikas Kumar, Francisco García, Martí Nadal & José L. Domingo. (2014) A PBPK model to estimate PCDD/F levels in adipose tissue: Comparison with experimental values of residents near a hazardous waste incinerator. Environment International 73, pages 150-157.
Crossref
Crossref
Zhe-Yi Hu, Jingtao Lu & Yuansheng Zhao. (2014) A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans. British Journal of Pharmacology 171:11, pages 2778-2789.
Crossref
Crossref
Aleksandra Galetin. 2014. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
255
288
.
Carole E. Shardlow, Grant T. Generaux, Aarti H. Patel, Guoying Tai, Thuy Tran & Jackie C. Bloomer. (2013) Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development. Drug Metabolism and Disposition 41:12, pages 1994-2003.
Crossref
Crossref
Gerhard Glatting, Manuel Bardiès & Michael Lassmann. (2013) Treatment planning in molecular radiotherapy. Zeitschrift für Medizinische Physik 23:4, pages 262-269.
Crossref
Crossref
Henry T. Peng, Fethi Bouak, Oshin Vartanian & Bob Cheung. (2013) A physiologically based pharmacokinetics model for melatonin—Effects of light and routes of administration. International Journal of Pharmaceutics 458:1, pages 156-168.
Crossref
Crossref
Yanyan Li, Tao Zhang, Xiaoqin Li, Peng Zou, Steven J. Schwartz & Duxin Sun. (2013) Kinetics of sulforaphane in mice after consumption of sulforaphane-enriched broccoli sprout preparation. Molecular Nutrition & Food Research 57:12, pages 2128-2136.
Crossref
Crossref
Jennifer M. Daley, Ross J. Norstrom & Ken G. Drouillard. (2013) Tissue Distribution Kinetics of 2,2′,4,4′,5,5′-Hexachlorobiphenyl in Ringdoves After Oral Dosing. Bulletin of Environmental Contamination and Toxicology 91:4, pages 367-371.
Crossref
Crossref
Leijun Hu & Ryan J. Hansen. (2013) Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies. Journal of Pharmaceutical Sciences 102:9, pages 2898-2908.
Crossref
Crossref
Tao Zhang, Yanyan Li, Peng Zou, Jing‐yu Yu, Donna McEachern, Shaomeng Wang & Duxin Sun. (2013) Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM‐406/AT‐406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharmaceutics & Drug Disposition 34:6, pages 348-359.
Crossref
Crossref
HM Jones & K Rowland‐Yeo. (2013) Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development. CPT: Pharmacometrics & Systems Pharmacology 2:8, pages 1-12.
Crossref
Crossref
Motao Zhu, Sarah Perrett & Guangjun Nie. (2012) Understanding the Particokinetics of Engineered Nanomaterials for Safe and Effective Therapeutic Applications. Small 9:9-10, pages 1619-1634.
Crossref
Crossref
Markus Krauss, Rolf Burghaus, Jörg Lippert, Mikko Niemi, Pertti Neuvonen, Andreas Schuppert, Stefan Willmann, Lars Kuepfer & Linus Görlitz. (2013) Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. In Silico Pharmacology 1:1.
Crossref
Crossref
Katherine L. Gill, Michael Gertz, J. Brian Houston & Aleksandra Galetin. (2013) Application of a Physiologically Based Pharmacokinetic Model to Assess Propofol Hepatic and Renal Glucuronidation in Isolation: Utility of In Vitro and In Vivo Data. Drug Metabolism and Disposition 41:4, pages 744-753.
Crossref
Crossref
DR Mould & RN Upton. (2013) Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods. CPT: Pharmacometrics & Systems Pharmacology 2:4, pages 1-14.
Crossref
Crossref
Jialin Mao, Theodore R. Johnson, Zhongzhou Shen & Shinji Yamazaki. (2013) Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes. Drug Metabolism and Disposition 41:2, pages 343-352.
Crossref
Crossref
Claudia Suenderhauf & Neil Parrott. (2012) A Physiologically Based Pharmacokinetic Model of the Minipig: Data Compilation and Model Implementation. Pharmaceutical Research 30:1, pages 1-15.
Crossref
Crossref
Jens Niklas, Juan G Diaz Ochoa, Joachim Bucher & Klaus Mauch. (2012) Quantitative Evaluation and Prediction of Drug Effects and Toxicological Risk Using Mechanistic Multiscale Models. Molecular Informatics 32:1, pages 14-23.
Crossref
Crossref
J Lippert, M Brosch, O von Kampen, M Meyer, H.‐U Siegmund, C Schafmayer, T Becker, B Laffert, L Görlitz, S Schreiber, PJ Neuvonen, M Niemi, J Hampe & L Kuepfer. (2012) A Mechanistic, Model‐Based Approach to Safety Assessment in Clinical Development. CPT: Pharmacometrics & Systems Pharmacology 1:11, pages 1-8.
Crossref
Crossref
Kathryn Ball, François Bouzom, Jean-Michel Scherrmann, Bernard Walther & Xavier Declèves. (2012) Development of a Physiologically Based Pharmacokinetic Model for the Rat Central Nervous System and Determination of an In Vitro–In Vivo Scaling Methodology for the Blood–Brain Barrier Permeability of Two Transporter Substrates, Morphine and Oxycodone. Journal of Pharmaceutical Sciences 101:11, pages 4277-4292.
Crossref
Crossref
Markus Krauss, Stephan Schaller, Steffen Borchers, Rolf Findeisen, Jörg Lippert & Lars Kuepfer. (2012) Integrating Cellular Metabolism into a Multiscale Whole-Body Model. PLoS Computational Biology 8:10, pages e1002750.
Crossref
Crossref
Richard N. Upton, David J. R. Foster, Lona L. Christrup, Ola Dale, Kristin Moksnes & Lars Popper. (2012) A physiologically-based recirculatory meta-model for nasal fentanyl in man. Journal of Pharmacokinetics and Pharmacodynamics 39:5, pages 561-576.
Crossref
Crossref
DR Mould & RN Upton. (2012) Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development. CPT: Pharmacometrics & Systems Pharmacology 1:9, pages 1-14.
Crossref
Crossref
Pranab K. Sen. 2001. Encyclopedia of Environmetrics. Encyclopedia of Environmetrics.
Stefan Willmann, Kirstin Thelen & Jörg Lippert. (2012) Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®. Journal of Pharmacy and Pharmacology 64:7, pages 997-1007.
Crossref
Crossref
Alexander V. LyubimovFrédéric Y. Bois & Masoud Jamei. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
27
.
Michaela Meyer, Sebastian Schneckener, Bernd Ludewig, Lars Kuepfer & Joerg Lippert. (2012) Using Expression Data for Quantification of Active Processes in Physiologically Based Pharmacokinetic Modeling. Drug Metabolism and Disposition 40:5, pages 892-901.
Crossref
Crossref
Erik Sjögren, Ulf Bredberg & Hans Lennernäs. (2012) The Pharmacokinetics and Hepatic Disposition of Repaglinide in Pigs: Mechanistic Modeling of Metabolism and Transport. Molecular Pharmaceutics 9:4, pages 823-841.
Crossref
Crossref
Jianping Xie, Kristin M. Marano, Cody L. Wilson, Huimin Liu, Huamin Gan, Fuwei Xie & Ziad S. Naufal. (2012) A probabilistic risk assessment approach used to prioritize chemical constituents in mainstream smoke of cigarettes sold in China. Regulatory Toxicology and Pharmacology 62:2, pages 355-362.
Crossref
Crossref
François Bouzom, Kathryn Ball, Nathalie Perdaems & Bernard Walther. (2012) Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?. Biopharmaceutics & Drug Disposition 33:2, pages 55-71.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
401
406
.
John F. Graf, Bernhard J. Scholz & Maria I. Zavodszky. (2011) BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems. Journal of Pharmacokinetics and Pharmacodynamics 39:1, pages 37-54.
Crossref
Crossref
Aleš Prokop & Seth MichelsonAleš Prokop & Seth Michelson. 2012. Systems Biology in Biotech & Pharma. Systems Biology in Biotech & Pharma
77
85
.
Viness Pillay, Yahya E. Choonara, Pradeep Kumar, Valence M. K. Ndesendo & Lisa C. du Toit. 2012. Patenting Nanomedicines. Patenting Nanomedicines
49
96
.
Mingguang Li & Joshua Reineke. 2012. Nanotoxicity. Nanotoxicity
369
382
.
Lars Kuepfer, Jörg Lippert & Thomas Eissing. 2012. Advances in Systems Biology. Advances in Systems Biology
543
561
.
Ronald D. HoodPatrick J. Wier. 2011. Developmental and Reproductive Toxicology: A Practical Approach. Developmental and Reproductive Toxicology: A Practical Approach
518
541
.
Cheng Chang, Wonkyung Byon, Yifeng Lu, Leslie K. Jacobsen, Lori L. Badura, Aarti Sawant-Basak, Emily Miller, Jing Liu, Sarah Grimwood, Ellen Q. Wang & Tristan S. Maurer. (2011) Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans. The AAPS Journal 13:4, pages 565-575.
Crossref
Crossref
Joachim Bucher, Stephan Riedmaier, Anke Schnabel, Katrin Marcus, Gabriele Vacun, Thomas S Weiss, Wolfgang E Thasler, Andreas K Nüssler, Ulrich M Zanger & Matthias Reuss. (2011) A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes. BMC Systems Biology 5:1.
Crossref
Crossref
Peter Kletting, Sven N. Reske & Gerhard Glatting. (2011) Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: A simulation study. Zeitschrift für Medizinische Physik 21:4, pages 301-304.
Crossref
Crossref
Amit K. Shah & Sunil A. Agnihotri. (2011) Recent advances and novel strategies in pre-clinical formulation development: An overview. Journal of Controlled Release 156:3, pages 281-296.
Crossref
Crossref
Elizabeth Joshi. (2011) Book Review: Drug Development Perspectives: Considerations, Challenges and Strategies. Bioanalysis 3:12, pages 1317-1318.
Crossref
Crossref
Peter Kletting, Thomas Kull, Donald Bunjes, M. Luster, Sven N. Reske & Gerhard Glatting. (2011) Optimal preloading in radioimmunotherapy with anti-CD45 antibody. Medical Physics 38:5, pages 2572-2578.
Crossref
Crossref
Pardeep SidhuHenry T. PengBob CheungAndrea Edginton. (2011) Simulation of differential drug pharmacokinetics under heat and exercise stress using a physiologically based pharmacokinetic modeling approach. Canadian Journal of Physiology and Pharmacology 89:5, pages 365-382.
Crossref
Crossref
Sarah Adler, David Basketter, Stuart Creton, Olavi Pelkonen, Jan van Benthem, Valérie Zuang, Klaus Ejner Andersen, Alexandre Angers-Loustau, Aynur Aptula, Anna Bal-Price, Emilio Benfenati, Ulrike Bernauer, Jos Bessems, Frederic Y. Bois, Alan Boobis, Esther Brandon, Susanne Bremer, Thomas Broschard, Silvia Casati, Sandra Coecke, Raffaella Corvi, Mark Cronin, George Daston, Wolfgang Dekant, Susan Felter, Elise Grignard, Ursula Gundert-Remy, Tuula Heinonen, Ian Kimber, Jos Kleinjans, Hannu Komulainen, Reinhard Kreiling, Joachim Kreysa, Sofia Batista Leite, George Loizou, Gavin Maxwell, Paolo Mazzatorta, Sharon Munn, Stefan Pfuhler, Pascal Phrakonkham, Aldert Piersma, Albrecht Poth, Pilar Prieto, Guillermo Repetto, Vera Rogiers, Greet Schoeters, Michael Schwarz, Rositsa Serafimova, Hanna Tähti, Emanuela Testai, Joost van Delft, Henk van Loveren, Mathieu Vinken, Andrew Worth & José-Manuel Zaldivar. (2011) Alternative (non-animal) methods for cosmetics testing: current status and future prospects—2010. Archives of Toxicology 85:5, pages 367-485.
Crossref
Crossref
C. Andrew Boswell, Gregory Z. Ferl, Eduardo E. Mundo, Daniela Bumbaca, Michelle G. Schweiger, Frank-Peter Theil, Paul J. Fielder & Leslie A. Khawli. (2011) Effects of Anti-VEGF on Predicted Antibody Biodistribution: Roles of Vascular Volume, Interstitial Volume, and Blood Flow. PLoS ONE 6:3, pages e17874.
Crossref
Crossref
Xinyuan Zhang, Robert A. Lionberger, Barbara M. Davit & Lawrence X. Yu. (2011) Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development. The AAPS Journal 13:1, pages 59-71.
Crossref
Crossref
Shinji Yamazaki, Judith Skaptason, David Romero, Sylvia Vekich, Hannah M. Jones, Weiwei Tan, Keith D. Wilner & Tatiana Koudriakova. (2011) Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model. Drug Metabolism and Disposition 39:3, pages 383-393.
Crossref
Crossref
Malcolm RowlandCarl Peck & Geoffrey Tucker. (2011) Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science. Annual Review of Pharmacology and Toxicology 51:1, pages 45-73.
Crossref
Crossref
Feras Khalil & Stephanie Läer. (2011) Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development. Journal of Biomedicine and Biotechnology 2011, pages 1-13.
Crossref
Crossref
Vikash Sinha & Holly H. C. Kimko. 2011. Clinical Trial Simulations. Clinical Trial Simulations
483
499
.
Alan F Sasso, Sastry S Isukapalli & Panos G Georgopoulos. (2010) A generalized physiologically-based toxicokinetic modeling system for chemical mixtures containing metals. Theoretical Biology and Medical Modelling 7:1.
Crossref
Crossref
Frédéric Y. Bois, Masoud Jamei & Harvey J. Clewell. (2010) PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278:3, pages 256-267.
Crossref
Crossref
Mingguang Li, Khuloud T. Al-Jamal, Kostas Kostarelos & Joshua Reineke. (2010) Physiologically Based Pharmacokinetic Modeling of Nanoparticles. ACS Nano 4:11, pages 6303-6317.
Crossref
Crossref
Gary Eichenbaum, Vangala Subrahmanyam & Alfred P. Tonelli. 2010. Early Drug Development. Early Drug Development
309
359
.
Suzanne Skolnik, Xuena Lin, Jianling Wang, Xiao-Hui Chen, Timothy He & Bailin Zhang. (2010) Towards Prediction of In Vivo Intestinal Absorption Using a 96-Well Caco-2 Assay. Journal of Pharmaceutical Sciences 99:7, pages 3246-3265.
Crossref
Crossref
Peter Kletting, Thomas Kull, Donald Bunjes, Bettina Mahren, Markus Luster, Sven N. Reske & Gerhard Glatting. (2010) Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model. Journal of Nuclear Medicine 51:3, pages 484-491.
Crossref
Crossref
Shengping Qin, Jai Woong Seo, Hua Zhang, Jinyi Qi, Fitz-Roy E. Curry & Katherine W. Ferrara. (2009) An Imaging-Driven Model for Liposomal Stability and Circulation. Molecular Pharmaceutics 7:1, pages 12-21.
Crossref
Crossref
Stefan Willmann, Andrea N Edginton, Marcus Kleine-Besten, Ekarat Jantratid, Kirstin Thelen & Jennifer B Dressman. (2009) Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. Journal of Pharmacy and Pharmacology 61:7, pages 891-899.
Crossref
Crossref
Loren M. Berry, Jonathan Roberts, Xuhai Be, Zhiyang Zhao & Min-Hwa Jasmine Lin. (2010)
Prediction of
V
ss
from In Vitro Tissue-Binding Studies
. Drug Metabolism and Disposition 38:1, pages 115-121.
Crossref
Crossref
G. Johanson. 2010. Comprehensive Toxicology. Comprehensive Toxicology
153
177
.
Agnès Poirier, Christoph Funk, Jean-Michel Scherrmann & Thierry Lavé. (2009) Mechanistic Modeling of Hepatic Transport from Cells to Whole Body: Application to Napsagatran and Fexofenadine. Molecular Pharmaceutics 6:6, pages 1716-1733.
Crossref
Crossref
Peter Thygesen, Panos Macheras & Achiel Van Peer. (2009) Physiologically-Based PK/PD Modelling of Therapeutic Macromolecules. Pharmaceutical Research 26:12, pages 2543-2550.
Crossref
Crossref
Richard Weaver & Roeline Jochemsen. 2009. International Pharmaceutical Product Registration, Second Edition. International Pharmaceutical Product Registration, Second Edition
336
376
.
Masoud Jamei, Gemma L. Dickinson & Amin Rostami-Hodjegan. (2009) A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates. Drug Metabolism and Pharmacokinetics 24:1, pages 53-75.
Crossref
Crossref
Donald E. Mager, Sukyung Woo & William J. Jusko. (2009) Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans. Drug Metabolism and Pharmacokinetics 24:1, pages 16-24.
Crossref
Crossref
Stefan Willmann. (2009)
Das
In‐silico‐Child
. Können Computer‐Simulationen klinisch‐pharmakokinetische Studien ersetzen?
. Pharmazie in unserer Zeit 38:1, pages 62-67.
Crossref
Crossref
F. Bouzom & B. Walther. (2008) Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling. Fundamental & Clinical Pharmacology 22:6, pages 579-587.
Crossref
Crossref
Kok-Yong Seng, Ivan Nestorov & Paolo Vicini. (2008) Physiologically Based Pharmacokinetic Modeling of Drug Disposition in Rat and Human: A Fuzzy Arithmetic Approach. Pharmaceutical Research 25:8, pages 1771-1781.
Crossref
Crossref
Sheila Annie Peters. (2008) Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Lineshape Analysis. Clinical Pharmacokinetics 47:4, pages 261-275.
Crossref
Crossref
Balaji M. Agoram, Steven W. Martin & Piet H. van der Graaf. (2007) The role of mechanism-based pharmacokinetic?pharmacodynamic (PK?PD) modelling in translational research of biologics. Drug Discovery Today 12:23-24, pages 1018-1024.
Crossref
Crossref
K. Sandy Pang, Michael Weiss & Panos Macheras. (2007) Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts. The AAPS Journal 9:2, pages E268-E283.
Crossref
Crossref